Cytokine storm and targeted therapy in hemophagocytic lymphohistiocytosis

No abstract is available for this paper.

• Publication year

  2022

• Venue

  Immunologic research

• Publication date

  2022-07-11

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s12026-022-09285-wPMID 35819695
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Hemophagocytic lymphohistiocytosis: update on pathogenesis, diagnosis, and treatment].

  2021influential reference
• Clinical Characteristics of Adult Hemophagocytic Lymphohistiocytosis in the Emergency Department

  2021cited by this paper
• Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis

  2021influential reference
• Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis

  2020cited by this paper
• Pediatric Hemophagocytic Lymphohistiocytosis (HLH).

  2020cited by this paper
• Cell Versus Cytokine – Directed Therapies for Hemophagocytic Lymphohistiocytosis (HLH) in Inborn Errors of Immunity

  2020cited by this paper
• Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis.

  2020cited by this paper
• IL6-R blocking with tocilizumab in critically ill patients with hemophagocytic syndrome

  2020cited by this paper
• Roles of IFN-γ in tumor progression and regression: a review

  2020cited by this paper
• JAK/STAT pathway inhibition sensitizes CD8 T cells to dexamethasone-induced apoptosis in hyperinflammation.

  2020cited by this paper
• Natural Killer Cells in Systemic Autoinflammatory Diseases: A Focus on Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome

  2020cited by this paper
• Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis

  2020cited by this paper
• IL-18/IL-18BP and IL-22/IL-22BP: Two interrelated couples with therapeutic potential.

  2019cited by this paper
• Targeting Interleukin-6 Signaling in Clinic.

  2019influential reference
• Transforming Growth Factor-β Signaling in Immunity and Cancer.

  2019cited by this paper
• The Immunology of Macrophage Activation Syndrome

  2019influential reference
• Emapalumab: First Global Approval

  2019cited by this paper
• Targeting IL-10 Family Cytokines for the Treatment of Human Diseases.

  2019cited by this paper
• Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis.

  2019cited by this paper
• Mechanisms of Action of Ruxolitinib in Murine Models of Hemophagocytic Lymphohistiocytosis.

  2019cited by this paper
• Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature

  2018cited by this paper
• IFNγ: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy

  2018cited by this paper
• Overview of the IL‐1 family in innate inflammation and acquired immunity

  2018cited by this paper
• [Haemophagocytic syndromes: The importance of early diagnosis and treatment].

  2018cited by this paper
• MicroRNA networks associated with active systemic juvenile idiopathic arthritis regulate CD163 expression and anti‐inflammatory functions in macrophages through two distinct mechanisms

  2018cited by this paper
• Translational and clinical advances in JAK‐STAT biology: The present and future of jakinibs

  2018cited by this paper
• Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome.

  2018cited by this paper
• Macrophage activation syndrome in a patient with axial spondyloarthritis on adalimumab

  2018cited by this paper
• Effect of Biologic Therapy on Clinical and Laboratory Features of Macrophage Activation Syndrome Associated With Systemic Juvenile Idiopathic Arthritis

  2018cited by this paper
• Contextual determinants of TGFβ action in development, immunity and cancer

  2018cited by this paper
• Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study.

  2017cited by this paper
• Transforming growth factor-β: A therapeutic target for cancer

  2017cited by this paper
• The transcription factor musculin promotes the unidirectional development of peripheral Treg cells by suppressing the TH2 transcriptional program

  2017cited by this paper
• Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition.

  2017cited by this paper
• A consensus review on malignancy‐associated hemophagocytic lymphohistiocytosis in adults

  2017cited by this paper
• Similar but not the same: Differential diagnosis of HLH and sepsis.

  2017cited by this paper
• Neurologic Manifestations of Systemic Disease ( N Scolding and C Rice , Section Editors ) How to Treat Involvement of the Central Nervous System in Hemophagocytic Lymphohistiocytosis ?

  2017cited by this paper
• Interleukin‐18: Biological properties and role in disease pathogenesis

  2017influential reference
• Inflammasome activation and assembly at a glance

  2017cited by this paper
• JAK inhibition as a therapeutic strategy for immune and inflammatory diseases

  2017cited by this paper
• Hemophagocytic syndromes (HPSs) including hemophagocytic lymphohistiocytosis (HLH) in adults: A systematic scoping review.

  2016cited by this paper
• Haemophagocytic lymphohistiocytosis (HLH): a rare but potentially fatal association with Plasmodium vivax malaria

  2016cited by this paper
• Hemophagocytic lymphohistiocytosis: Pathogenesis, diagnosis, and management

  2016cited by this paper
• IL-2 consumption by highly activated CD8 T cells induces regulatory T-cell dysfunction in patients with hemophagocytic lymphohistiocytosis.

  2016influential reference
• Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab

  2016cited by this paper
• Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice.

  2016cited by this paper
• Macrophage activation syndrome in the era of biologic therapy

  2016influential reference
• Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies.

  2015influential reference
• Incidence and clinical presentation of primary hemophagocytic lymphohistiocytosis in Sweden

  2015cited by this paper
• Inhibition of Natural Killer Cell Cytotoxicity by Interleukin‐6: Implications for the Pathogenesis of Macrophage Activation Syndrome

  2015cited by this paper
• Malignancy‐associated haemophagocytic lymphohistiocytosis in children and adolescents

  2015influential reference
• Cytokine balance and cytokine-driven natural killer cell dysfunction in systemic juvenile idiopathic arthritis.

  2015cited by this paper
• Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis under Treatment with Tocilizumab

  2015cited by this paper
• The JAK-STAT pathway: impact on human disease and therapeutic intervention.

  2015cited by this paper
• Macrophage Activation Syndrome.

  2015cited by this paper
• Hemophagocytic syndromes--an update.

  2014cited by this paper
• Adult haemophagocytic syndrome.

  2014cited by this paper
• H-ferritin ferroxidase induces cytoprotective pathways and inhibits microvascular stasis in transgenic sickle mice

  2014cited by this paper
• Transforming Growth Factor-β Signaling

  2013cited by this paper
• Interleukin-18 and IL-18 Binding Protein

  2013cited by this paper
• Interferon-γ mediates anemia but is dispensable for fulminant toll-like receptor 9-induced macrophage activation syndrome and hemophagocytosis in mice.

  2013cited by this paper
• Regulatory T cells: mechanisms of differentiation and function.

  2012influential reference
• Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: the diagnostic significance of interleukin-18 and interleukin-6.

  2012cited by this paper
• The transcription factor Sox4 is a downstream target of signaling by the cytokine TGF-β and suppresses TH2 differentiation

  2012cited by this paper
• Amplification of the response to Toll-like receptor ligands by prolonged exposure to interleukin-6 in mice: implication for the pathogenesis of macrophage activation syndrome.

  2012cited by this paper
• Protection from Inflammatory Organ Damage in a Murine Model of Hemophagocytic Lymphohistiocytosis Using Treatment with IL-18 Binding Protein

  2012influential reference
• Serum Neopterin Levels as a Diagnostic Marker of Hemophagocytic Lymphohistiocytosis Syndrome

  2011cited by this paper
• Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients.

  2011cited by this paper
• IL-10 elicits IFNγ-dependent tumor immune surveillance.

  2011cited by this paper
• Hemophagocytosis causes a consumptive anemia of inflammation

  2011cited by this paper
• Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice.

  2011cited by this paper
• Regulation and functions of the IL-10 family of cytokines in inflammation and disease.

  2011cited by this paper
• Understanding the mechanism of IL-1β secretion

  2011cited by this paper
• Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol.

  2011cited by this paper
• Clinical significance of cloned expansion and CD5 down-regulation in Epstein-Barr Virus (EBV)-infected CD8+ T lymphocytes in EBV-associated hemophagocytic lymphohistiocytosis.

  2010cited by this paper
• Hemophagocytic lymphohistiocytosis in Texas: Observations on ethnicity and race

  2010influential reference
• Regulatory T cells in tumor immunity

  2010cited by this paper
• Transforming growth factor-beta signaling curbs thymic negative selection promoting regulatory T cell development.

  2010cited by this paper
• Macrophage activation syndrome: serological markers and treatment with anti-thymocyte globulin.

  2009cited by this paper
• Experience With Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome at a Single Institution

  2009cited by this paper
• The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis.

  2008cited by this paper
• A Griscelli syndrome type 2 murine model of hemophagocytic lymphohistiocytosis (HLH)

  2008cited by this paper
• Association of transforming growth factor-β1 gene polymorphism in the development of Epstein-Barr virus-related hematologic diseases

  2007cited by this paper
• Hemophagocytic syndromes.

  2007cited by this paper
• HLH‐2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis

  2007cited by this paper
• Yin and yang interplay of IFN-gamma in inflammation and autoimmune disease.

  2007cited by this paper
• Specific gene expression profiles in systemic juvenile idiopathic arthritis.

  2007cited by this paper
• Constitutive Endocytosis of CD163 Mediates Hemoglobin-Heme Uptake and Determines the Noninflammatory and Protective Transcriptional Response of Macrophages to Hemoglobin

  2006influential reference
• TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance

  2005cited by this paper
• IL-12 family members: differential kinetics of their TLR4-mediated induction by Salmonella enteritidis and the impact of IL-10 in bone marrow-derived macrophages.

  2005cited by this paper
• Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade

  2005cited by this paper
• [Macrophage activation syndrome after treatment with infliximab for fistulated Crohn's disease].

  2005cited by this paper
• Macrophage Activation Syndrome in a Child with Systemic Juvenile Rheumatoid Arthritis

  2005influential reference
• Interferon- : an overview of signals, mechanisms and functions

  2004cited by this paper
• Interferon-gamma: an overview of signals, mechanisms and functions.

  2004cited by this paper
• Differences in signaling pathways by IL-1beta and IL-18.

  2004cited by this paper
• An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder.

  2004influential reference
• The chemokine system in diverse forms of macrophage activation and polarization.

  2004cited by this paper
• The many faces of macrophage activation

  2003cited by this paper
• Principles of interleukin (IL)-6-type cytokine signalling and its regulation.

  2003cited by this paper

• Neurological Involvement in Adult‐Onset Secondary Hemophagocytic Lymphohistiocytosis: Clinical Features and Prognostic Implications

  2026cites this paper
• Unraveling the enigma of Epstein-Barr virus: pathogenesis, diagnosis, and cutting-edge treatments for EBV-HLH

  2026cites this paper
• Cytokine Profiles in Children with Primary Hemophagocytic Lymphohistiocytosis and Macrophage Activation Syndrome

  2026cites this paper
• Utility of anakinra in Crimean Congo haemorrhagic fever with haemophagocyctic lymphohistiocytosis: a case report.

  2025cites this paper
• Biomarkers of pediatric Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis through single-cell transcriptomics

  2025cites this paper
• Serum cytokine pattern for the early identification of hemophagocytic lymphohistiocytosis in diffuse large B-cell lymphoma.

  2025cites this paper
• Imaging in Hemophagocytic Lymphohistiocytosis: A Comprehensive Pictorial Essay

  2025cites this paper
• Tislelizumab-induced hemophagocytic lymphohistiocytosis in a patient with microsatellite instability-high colon cancer and coexisting systemic lupus erythematosus: a case report and literature review

  2025cites this paper
• TSCytoPred: a deep learning framework for inferring cytokine expression trajectories from irregular longitudinal gene expression data to enhance multi-omics analyses

  2025cites this paper
• Nomogram for predicting the 30- and 90-day prognoses of hemophagocytic lymphohistiocytosis patients: a multicenter and retrospective study

  2025cites this paper
• [Childhood hemophagocytic lymphohistiocytosis with pancytopenia triggered by leishmaniasis].

  2025cites this paper
• Age-associated immune dysregulation and B cell dysfunction drive severe outcomes in SFTSV infection

  2025cites this paper
• The lncRNA LINC02446 promotes tumor progression and HLH occurrence by regulating the expression of KLRs and IL-10 in EBV-NK-LPDs.

  2025cites this paper
• Hemophagocytic lymphohistiocytosis: current treatment advances, emerging targeted therapy and underlying mechanisms

  2024cites this paper
• Prognostic Factors of Adult Hemophagocytic Lymphohistiocytosis and Clinical Utility of HLH-2004 Diagnostic Criteria and HScore: A Real-World Multicenter Study from Thailand

  2024cites this paper
• The anti‐inflammatory effect of metformin: The molecular targets

  2024cites this paper
• Secondary hemophagocytic syndrome in an acquired immunodeficiency syndrome and Alpha-thalassemia patient infected with Talaromyces marneffei: A case report and literature review

  2024cites this paper
• Single-Cell Transcriptomic Analysis of Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis

  2024cites this paper
• The impact of immunosuppression on the mortality and hospitalization of Monkeypox: a systematic review and meta-analysis of the 2022 outbreak

  2024cites this paper
• Acute kidney injury in critical care: complications of hemophagocytic lymphohistiocytosis

  2024cites this paper
• Into the storm: the imbalance in the yin-yang immune response as the commonality of cytokine storm syndromes

  2024cites this paper
• Ruxolitinib‐based regimen in children with autoimmune disease or autoinflammatory disease‐related haemophagocytic lymphohistiocytosis

  2024cites this paper
• A predictive model for Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis

  2024cites this paper
• Ehrlichia-Induced Hemophagocytic Lymphohistiocytosis (HLH) With No Response to Doxycycline Treatment

  2023cites this paper
• The signature and predictive value of immune parameters in patients with secondary hemophagocytic lymphohistiocytosis.

  2023cites this paper
• An analysis of reported cases of hemophagocytic lymphohistiocytosis (HLH) after COVID-19 vaccination

  2023cites this paper
• BPOZ-2 is a negative regulator of the NLPR3 inflammasome contributing to SARS-CoV-2-induced hyperinflammation

  2023cites this paper
• Interplay of host and viral factors in inflammatory pathway mediated cytokine storm during RNA virus infection

  2023cites this paper
• Anaplasmosis-Induced Hemophagocytic Lymphohistiocytosis: A Case Report and Review of the Literature

  2023cites this paper
• Did variants in inborn errors of immunity genes contribute to the extinction of Neanderthals?

  2022cites this paper